Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today reported financial results for the first quarter ended March 31, 2026, and provided a comprehensive business update. CEO Commentary: “Our progress in the first quarter of 2026 reflects continued execution against our core mission of developing therapeutics ca.